CUAMC
LFCR icon

China Universal Asset Management Company’s Lifecore Biomedical LFCR Stock Holding History

China Universal Asset Management Company’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Sell
5,970
-679
-10% -$3.42K ﹤0.01% 483
2026
Q1 		$24.7K Buy
6,649
+544
+9% +$3.76K ﹤0.01% 490
2025
Q4 		$49.9K Buy
+6,105
New +$45.2K ﹤0.01% 452

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

China Universal Asset Management Company's LFCR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Lifecore Biomedical (LFCR) stake by 10% in Q2 2026, selling an estimated $3.42K and leaving 5,970 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #483.

China Universal Asset Management Company first reported a position in LFCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $49.9K in Q4 2025. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • China Universal Asset Management Company held 5,970 shares of Lifecore Biomedical worth $31.3K as of Q2 2026.
  • China Universal Asset Management Company sold 679 Lifecore Biomedical shares in Q2 2026, an estimated $3.42K.
  • Lifecore Biomedical made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #483 holding.
  • China Universal Asset Management Company first reported a position in Lifecore Biomedical in Q4 2025 and has held it in 3 quarters since.
  • China Universal Asset Management Company's Lifecore Biomedical position peaked at $49.9K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.